Clinical Trials Logo

Clinical Trial Summary

Supply of Normal Human Immunoglobulins (NHIg) has been in steady tension for almost 15 years in the world. The scarcity of raw material, manufacturing time by industries, and increase consumptions are some of the causes. These phenomena has been accentuated for two years in the context of pandemic. Faced these difficulties, the french National Medication Security Agency (ANSM) , in collaboration with health professionals and patients associations concerned, established a hierarchy of indications of NHIg to prioritize NHIg for patients without therapeutic alternative (2013 and 2019). Its use is sometimes complex, particularly in the indications where the use of NHIg must combine clinico-biological criteria and/or previous treatment lines.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06027450
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact Laure Deville, Dr
Phone +33142494292
Email laure.deville@aphp.fr
Status Not yet recruiting
Phase
Start date September 1, 2023
Completion date December 1, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05856396 - Maternal Determinants of Infant Immunity to Pertussis Phase 4
Completed NCT04816942 - Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt Phase 3